



Episealer® included in the Swedish Knee Arthroplasty Register 2025

Episurf Medical (Nasdaq: EPIS B) today announces that the company's knee implant Episealer® has been included in the 2025 Annual Report of the Swedish Arthroplasty Register. Data for Episealer®, reported under the category Partial Resurfacing Implant, comprises a total of 87 registered implants and demonstrate a revision rate of 9% at eight years of follow-up. By comparison, revision rates at the same follow-up interval of 9% are reported for unicompartmental knee arthroplasty (UKA) in patients aged 55–74 years, and 13% in patients younger than 55 years. Episealer® is the only implant presented in the category Partial Resurfacing Implant.

The Swedish Knee Arthroplasty Register has for more than 50 years collected and presented follow-up data on different implants. The register is used globally and is continuously cited by researchers and orthopaedic surgeons worldwide.

"I am extremely proud of this milestone, which clearly demonstrates the progress we have achieved. Securing robust data in the Swedish Arthroplasty Register is an accomplishment in itself; doing so as a novel treatment, and as the sole provider within a segment, represents a particularly noteworthy achievement. The Episealer® implant is now included with a substantial body of long-term data, highlighting the clinical importance of the product we have introduced to the orthopaedic market. This provides a well-functioning alternative for a large group of patients who previously faced major joint replacement procedures, often prematurely," says Prof. Leif Ryd, Senior Medical Advisor and Board Member, Episurf Medical.

The full report can be downloaded via the Swedish Arthroplasty Register's website; <http://slr.registercentrum.se/>. Episealer® has previously been included in the register with smaller data sets.

For more information, please contact:

Pål Ryfors, CEO and interim CFO, Episurf Medical
Tel: +46 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.